타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Prevail Therapeutics·Ann Arbor Stage IIB Hodgkin Lympho… 178 trials | ||
|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Brentuximab Vedotin (Bv) | Methylprednisolone |
Overview Company | Roche / Genentech | Seagen / Takeda | Prevail Therapeutics |
Overview Modality | ADC | ADC | ADC |
Overview Target | FRα | Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Large B-Cell Lymphoma | Hodgkin Lymphoma (Category) | Parkinson Disease |
Overview Phase | PHASE_3 | APPROVED | PHASE_3 |
Overview Status | RECRUITING | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Standard Database | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | Vedotin: A Retrospective Cohort Study from a Te | deruxtecan plus sintilimab: a case report |
Technology Linker | linker, or payload that have limited their development | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Targeting of the Bradykinin B2 Receptor | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | CD20 expression | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — |
Clinical Program phase | PHASE_3 | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Rat | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Prevail Therapeutics·Ann Arbor Stage IIB Hodgkin Lympho… 178 trials | ||
|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Brentuximab Vedotin (Bv) | Methylprednisolone |
Overview Company | Roche / Genentech | Seagen / Takeda | Prevail Therapeutics |
Overview Modality | ADC | ADC | ADC |
Overview Target | FRα | Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Large B-Cell Lymphoma | Hodgkin Lymphoma (Category) | Parkinson Disease |
Overview Phase | PHASE_3 | APPROVED | PHASE_3 |
Overview Status | RECRUITING | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Standard Database | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | Vedotin: A Retrospective Cohort Study from a Te | deruxtecan plus sintilimab: a case report |
Technology Linker | linker, or payload that have limited their development | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Targeting of the Bradykinin B2 Receptor | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | CD20 expression | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — |
Clinical Program phase | PHASE_3 | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Rat | — | — |
추천 비교
추천 비교